News

The growing global burden of neuropsychiatric disorders is a critical driver for the treatment market. With over 9.1 million annual deaths attributed to neurological diseases and an additional 8 ...
Compass Pathways has announced that its investigational psilocybin therapy, COMP360, met the primary endpoint in its Phase 3 ...
A single dose of a synthetic psilocybin was found to improve symptoms in patients with treatment-resistant depression.
Compass Pathways took a 50% on June 23 hit after a lukewarm trial, but long-term bulls see upside in psychedelics.
An Iowa lawmaker who had pushed for the passage Gov. Kim Reynolds’ decision to veto a bill pertaining to the psychoactive ...
Though caution is required when the data haven't been published, it could be a landmark in the drug's journey toward FDA ...
Compass Pathways plc downgraded to Hold after mixed trial results. Explore upcoming catalysts in depression treatment and ...
The UK-based firm earlier announced that it had met the primary endpoint in the ongoing 258-patient Phase III COMP005 trial, ...
Stifel said the plunge in Compass Pathways shares was “significantly overdone” after data showed that the company’s COMP360 ...
A single dose of a synthetic form of psilocybin is safe and clinically meaningful in reducing treatment-resistant depression, ...
Although the company withheld detailed findings from the study of treatment-resistant depression, analysts at Stifel called ...
COMPASS Pathways Plc (NASDAQ:CMPS) stock is trading lower on Monday. The company announced it reached its primary endpoint in ...